Halozyme Therapeutics logged a -0.9% change during today's afternoon session, and is now trading at a price of $42.57 per share. The S&P 500 index moved -0.0%. HALO's trading volume is 355,605 compared to the stock's average volume of 1,189,556.
Halozyme Therapeutics trades -15.87% away from its average analyst target price of $50.6 per share. The 10 analysts following the stock have set target prices ranging from $26.0 to $72.0, and on average have given Halozyme Therapeutics a rating of buy.
Anyone interested in buying HALO should be aware of the facts below:
-
Halozyme Therapeutics's current price is 1099.3% above its Graham number of $3.55, which implies that at its current valuation it does not offer a margin of safety
-
Halozyme Therapeutics has moved -1036.9% over the last year, and the S&P 500 logged a change of 1216.7%
-
Based on its trailing earnings per share of 1.33, Halozyme Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 32.0 while the S&P 500 average is 15.97
-
HALO has a forward P/E ratio of 11.7 based on its forward 12 month price to earnings (EPS) of $3.65 per share
-
The company has a price to earnings growth (PEG) ratio of 0.64 — a number near or below 1 signifying that Halozyme Therapeutics is fairly valued compared to its estimated growth potential
-
Its Price to Book (P/B) ratio is 85.14 compared to its sector average of 4.16
-
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
-
Based in San Diego, the company has 393 full time employees and a market cap of $5.61 Billion.